The drugmaker Gilead has set the price for its coronavirus treatment remdesivir at $390 per vial for the U.S. government and developed countries.
That puts the price of a five-day treatment course at $2,340 per patient for people enrolled in federal health programs like Medicare and Medicaid — but private insurers will pay $520 per vial, or $3,120 for five days of treatment, the company said Monday. The U.S. is the only country for which Gilead has set tiered pricing.A senior HHS official said Monday during a background briefing that the Department of Veterans Affairs helped to negotiate the lower price for government programs.
The federal government has secured enough of the antiviral drug to treat more than 500,000 patients in hospitals through September, HHS said Monday. That amounts to Gilead's entire planned production run for July and 90 percent of its production in August and September. The government has also reservedThe health department and states will manage how the drug is allocated to U.S. hospitals through September.
Under the plan, HHS will allocate remdesivir doses to state health departments based on need, and states will then allocate doses to hospitals. Those facilities will then be able to purchase the drug through Gilead's distributor, AmerisourceBergen.The company argues that, at the price it will charge, the drug could save hospitals about $12,000 per patient in treatment costs.
'five-day treatment course at $2,340 per patient' LOL DOWN from MSRP of $5,080 (€4,532) per 10-day course, COMPETITIVE with generic brand 5,000 - 6,000 INR (€59-€71) Save 4 days off your 12-60 day expected recovery. Its fire sale and a floor wax!
For the record: This replaces a deleted thread that misstated the price for remdesivir in the U.S. and the nature of the government's agreement with Gilead.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: HealthyWomen - 🏆 29. / 68 Read more »